The pharmacogenomics of selective serotonin reuptake inhibitors
Antidepressant medications are frequently used as the first line of treatment for depression. However, their effectiveness is highly variable and influenced by genetic factors. Recently, pharmacogenetic studies, including candidate-gene, genome-wide association studies or polygenic risk scores, have attempted to uncover the genetic architecture of antidepressant response. Genetic variants in at least 27 genes are linked to antidepressant treatment response in both coding and non-coding genomic regions, but evidence is largely inconclusive due to the high polygenicity of the trait and limited cohort sizes in published studies. Future studies should increase the number and diversity of participants to yield sufficient statistical power to characterize the genetic underpinnings and biological mechanisms of treatment response, improve results generalizability and reduce racial health-related inequities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 23(2022), 10 vom: 01. Juli, Seite 597-607 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
García-Marín, Luis M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.08.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2022-0037 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341957550 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341957550 | ||
| 003 | DE-627 | ||
| 005 | 20231226012951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2022-0037 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341957550 | ||
| 035 | |a (NLM)35673953 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a García-Marín, Luis M |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The pharmacogenomics of selective serotonin reuptake inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antidepressant medications are frequently used as the first line of treatment for depression. However, their effectiveness is highly variable and influenced by genetic factors. Recently, pharmacogenetic studies, including candidate-gene, genome-wide association studies or polygenic risk scores, have attempted to uncover the genetic architecture of antidepressant response. Genetic variants in at least 27 genes are linked to antidepressant treatment response in both coding and non-coding genomic regions, but evidence is largely inconclusive due to the high polygenicity of the trait and limited cohort sizes in published studies. Future studies should increase the number and diversity of participants to yield sufficient statistical power to characterize the genetic underpinnings and biological mechanisms of treatment response, improve results generalizability and reduce racial health-related inequities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antidepressants | |
| 650 | 4 | |a candidate gene studies | |
| 650 | 4 | |a depression | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a genome-wide association studies | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a polygenic scores | |
| 650 | 4 | |a selective serotonin reuptake inhibitors | |
| 650 | 4 | |a treatment response | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Serotonin Uptake Inhibitors |2 NLM | |
| 700 | 1 | |a Rabinowitz, Jill A |e verfasserin |4 aut | |
| 700 | 1 | |a Ceja, Zuriel |e verfasserin |4 aut | |
| 700 | 1 | |a Alcauter, Sarael |e verfasserin |4 aut | |
| 700 | 1 | |a Medina-Rivera, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Rentería, Miguel E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 23(2022), 10 vom: 01. Juli, Seite 597-607 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:10 |g day:01 |g month:07 |g pages:597-607 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2022-0037 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 10 |b 01 |c 07 |h 597-607 | ||